LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
LIXT Earnings Report
FQ end 2026-06
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LB-100 | Phase 2 | Myelodysplastic Syndromes | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (LIXT) pipeline across Phase 2. Its lead program is LB-100 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s next FDA catalyst?→
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (LIXT) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LIXT biotech catalysts?→
Add LIXT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.